A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1(NF1)

Go Back to All Clinical Trials

A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727 IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1(NF1)

Brief description of study

The purpose of the study is to find out the safety and efficacy of the drug selumetinib in treating patients with low-grade glioma. We want to know if the drug can stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The goal of this study is to see if selumetinib works just as well as the standard treatment using carboplatin and vincristine for subjects with low-grade glioma.

Clinical Study Identifier: s20-00935

ClinicalTrials.gov Identifier: NCT04166409

Principal Investigator: Chana Glasser.

Other Investigators: Mark E Weinblatt, Ashish Massey, Lia Phillips, Christeen Azmy, Sylwia Jasinski.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies